Use of inotropic agents in patients with advanced heart failure: Lessons from recent trials and hopes for new agents

  • Metra M
  • Bettari L
  • Carubelli V
 et al. 
  • 16

    Readers

    Mendeley users who have this article in their library.
  • 13

    Citations

    Citations of this article.

Abstract

Abnormalities of cardiac function, with high intraventricular filling pressure and low cardiac output, play a central role in patients with heart failure. Agents with inotropic properties are potentially useful to correct these abnormalities. However, with the exception of digoxin, no inotropic agent has been associated with favourable effects on outcomes. This is likely related to the mechanism of action of current agents, which is based on an increase in intracellular cyclic adenosine monophosphate and calcium concentrations. Novel agents acting through different mechanisms, such as sarcoplasmic reticulum calcium uptake, cardiac myosin and myocardial metabolism, have the potential to improve myocardial efficiency and lower myocardial oxygen consumption. These characteristics might allow a haemodynamic improvement in the absence of untoward effects on the clinical course and prognosis of the patients.

Author-supplied keywords

  • Cardiotonics
  • Chronic-heart-failure
  • Digoxin
  • Dobutamine
  • Dopamine
  • Enoximone
  • Epoprostenol
  • Etomoxir
  • Istaroxime
  • Levosimendan
  • Milrinone
  • Omecamtiv-mecarbil
  • Perhexiline
  • Ranolazine
  • Research-and-development
  • Trimetazidine
  • Urocortin

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Marco Metra

  • Luca Bettari

  • Valentina Carubelli

  • Silvia Bugatti

  • Alessandra Dei Cas

  • Francesca Del Magro

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free